Preventative and therapeutic for autoimmune diseases OPN-201

workkinkajouBiotechnology

Dec 5, 2012 (4 years and 10 months ago)

178 views


PANEL Presentation


4 October 2004


Dr Mark Heffernan

CEO











Opsona’s Rationale



Focused on the development of therapeutics and preventatives for
a
utoimmune and inflammatory

diseases



Biopharmaceutical Program
:


Two lead drugs:


OPN
-
101:
Preventative and therapeutic for autoimmune diseases



OPN
-
201:

Preventative and therapeutic for autoimmune diseases



Toll
-
Like Receptor (TLR) Program:

in discussion with Pharma/Biotech re
drug discovery agreement



Small molecules:

including orally available molecules for treatment of
immune
-
mediated diseases



Exclusive option agreement to future technology





Founded in March 2004 with three leading immunologists from Trinity
College Dublin










The Opsona Model



The Opsona model:


Mark Heffernan, the University and 3
Academics agree to pursue an idea for
biotechnology start
-
up


Idea shows success and company in
negotiations to raise ~

5m A
-
round
finance


ALL WITHIN 9 MONTHS





The Founders




Dr Mark Heffernan (Co
-
Founder and CEO):



Senior
management at Metabolic Pharmaceuticals Ltd and Antisense
Therapeutics Ltd (Australia)



R&D and BD background


Dr Cormac Kilty (Chairman)


CEO Biotrin International


Chairman Irish BioIndustry Association


Prof Kingston Mills (Co
-
founder and Director):



Professor of Experimental Immunology, TCD,


International reputation in Immune regulation


Product commercialisation with Elan and Chiron


Prof Luke O’Neill (Co
-
founder and Director):



Director of the Biotechnology Institute, TCD


International expert in Toll receptor biology


Prof Dermot Kelleher (Co
-
founder and Director):



Director Dept Clin Med. TCD,


Gastroenterologist/Clinical Trials Expertise,


Technology licensing to Chiron Corp



Outstanding Science





Founders are international opinion leaders in basic and clinical
research.


Over 500 papers
-

Nature, Science, J. Exp Med., JBC,
Lancet, NEJM, Scientific American


Extensive industry collaborations


>

15m in funding and > 40 lab staff


Intellectual property and proprietary skills in
immunomodulation
-

Hot area!


Two lead drugs


with proof of principle animal experiments
established


Rich Pipeline of drugs and novel therapeutic approaches


Significant partnering interest from Pharma and Biotech
companies


Company Development






2005
2006
2007
2008
2009
2010
OPN-101
Pre-Clinical
Phase I
Phase II Clinical Trials
Phase III Clinical Trials
OPN-201
Research
Pre-Clinical
Phase I
Phase II Clinical Trials
Phase III
Toll receptor
Target ID..Target Screening…
In vivo
Pre-Clinical
Phase I
Phase II
Partnership
Pipeline
Research
Pre-Clinical
Phase I
Phase II
The Model Flow
-
Chart




November/December 2003:

MH talks with three key academics

December 15
th

2003:


TCD agrees to undertake feasibility




study with MH

January 2004:



Feasibility Commences






MH appoints Bus Dev Consultants

February 2004:



Receive

30k grant from EI (50%





cost of study)






Technology Assessment begins

March 2004:



Opsona Incorporates as a Pvt Ltd





company in Ireland






Business Plan commenced

April 2004:



Chairman appointed


Irish





Industry Leader

June 2004:



BPlan complete, VC approached.





MH attends major International





Biotech Conference, meets with





key Industry players

The Model Flow
-
Chart




July 2004:


International VCs Approached





Syndicate taking shape

August 2004:


Clinical plan commences


contract key



clinicians and consulting companies





Negotiations with TCD over License/Option



commence

October 2004:


Development of investor syndicate




Clinical plan complete

December 2004:

Close fundraising & commence





operations










Summary




Opsona:



start
-
up company with:


world
-
leading technology


key scientific founders


rich pipeline




complete proof
-
of
-
principle animal experiemts with
outstanding data with lead compound, OPN
-
101



Clinical trial to commence in 2005



Program to partner with Biotech/Pharma in 2004/2005


To succeed:


Get to know everyone fast!


Surround yourself with experienced opinion leaders and
advisors


Have story right before approaching VCs


Have access to enough funds for feasibility


Set tight milestones and deadlines



Contact







For investment and general enquiries contact:


Dr Mark Heffernan,


CEO


Opsona Therapeutics

Ltd
,


The O’Reilly Institute, Trinity College Dublin,


Dublin 2


email:
heffernan@opsona.com




Ph:+353 (0) 876 434 766,


Fax: +353 1 679 8039